How much is Parexel worth?
Biopharmaceutical company Parexel confirmed Tuesday morning it will be acquired by Pamplona Capital for $88.10 per share in cash, in a transaction valued at approximately $5 billion.
Who is the owner of Parexel?
The company was acquired by private equity firm Pamplona Capital Management for approximately $5.0 billion….Parexel.
| Type | Private |
|---|---|
| Founded | 1982 |
| Headquarters | Durham, North Carolina, U.S. Newton, Massachusetts, U.S. |
| Number of locations | 84+ facilities in 51+ countries |
| Key people | CEO: Jamie Macdonald |
Is Calyx owned by Parexel?
Calyx will be privately held by the same ownership group that has owned Parexel since 2017. Calyx will be led by Chief Executive Officer Gavin Nichols and the company will be headquartered in Nottingham, United Kingdom, and Durham, North Carolina. The new organization will employ approximately 2,300 employees.
Is Parexel a private company?
Four years after a private equity acquisition took Parexel private, the contract research organization is being acquired by two private equity firms for $8.5 billion. It’s the latest in a series of acquisitions to hit the CRO sector this year.
How much did Pamplona buy Parexel for?
People close to the matter said that the company drew interest from many private equity and investment companies, possibly wanting to cash in on its growth potential in the drug development industry. Pamplona finally bought Parexel in September 2017 for around $4.5 billion, or $88.10 per share in cash.
When did Parexel go private?
Parexel agreed to be taken private by Pamplona in 2017 for about $4.5 billion after activist investor Starboard Value LP urged the company to improve its margins and seek potential buyers.
Where is Parexel headquarters?
Auburndale, Newton, MA
Parexel/Headquarters
Has parexel been sold?
Parexel sold to EQT and Goldman Sachs for $8.5 billion.
Is parexel being sold?
Parexel is being sold for $8.5 billion by Pamplona Capital to Swedish private equity firm EQT and the private equity business of Goldman Sachs Asset Management.
Is parexel being acquired?
North Carolina-based clinical research organization (CRO) Parexel has announced the execution of a definitive merger agreement, under which the company will be purchased by EQT Private Equity and Goldman Sachs for $8.5b USD.
Is parexel a good company to work for?
Parexel is such a great place to work. The leadership team cares about the employees and is always open for suggestions with making it a great place to work. The culture is very supportive even in this difficult time with lack of resources. Career development is available for people who want to move up.
Is Parexel being acquired?
Why choose Parexel?
Through its clinical research operations, Parexel has participated in the development of nearly all of the top 50 drugs available at the midpoint of the first decade of the 21st century.
Does Parexel cause inflammation?
In March 2006, a Parexel-run trial on behalf of TeGenero, the now bankrupt German biotechnology firm, on its anti-inflammatory drug TGN1412 to treat rheumatoid arthritis, multiple sclerosis or leukaemia, caused severe inflammation and multiple organ failure in six healthy volunteers at a facility based at Northwick Park Hospital in London.
Who is the owner of the drug Parexel?
Parexel’s consulting and clinical trial work has helped establish many household drug brands and contributed to numerous successes in modern pharmacology . The company was acquired by private equity firm Pamplona Capital Management for approximately $5.0 billion. The deal closed in September of 2017.
Where can I find Parexel’s address?
PAREXEL International Corporation 195 West Street Waltham, Massachusetts 02451-1111